Agreement includes aggregate upfront and target nomination fees of up to $21.5 
million for up to 6 targets, and additional R&D and sales milestones plus 
tier-based mid-single- to low double-digit royalties.




Insilico Medicine, a clinical stage artificial intelligence (AI)-driven drug 
discovery company, announced a multi-year, multi-target strategic research 
collaboration with Sanofi. Under the terms of the agreement, the collaboration 
will leverage Insilico Medicine's AI platform, Pharma.AI, to advance drug 
development candidates for up to six new targets.

"We look forward to working with Insilico Medicine, a demonstrated leader in 
AI-powered drug discovery," said Changchun Xiao, Head of China Research at 
Sanofi. "This collaboration will leverage our complementary capabilities, as 
well as the co-location of our scientific teams, to boost the drug discovery 
efforts of the Sanofi Institute for Biomedical Research (SIBR), Sanofi's R&D 
center in China."

Under the terms of the agreement, Sanofi will pay Insilico Medicine a total of 
up to $21.5 million covering the upfront and target nomination fees to benefit 
from Insilico's end-to-end Pharma.AI platform and gain access to a team of 
interdisciplinary drug discovery scientists to identify, synthesize, and 
advance high-quality lead therapeutic compounds up to development candidate 
stage. Additional payments will be made if key research, development, and sales 
milestones are met, and could total more than $1.2 billion. The collaboration 
also establishes mid-single to up to low double-digit tiered royalties for any 
products developed.

"We are very happy to collaborate with Sanofi, a company with a clear strategy 
in AI-powered drug discovery," said Alex Zhavoronkov, PhD, CEO and founder of 
Insilico Medicine. "This close collaboration will allow Sanofi to immediately 
gain the capabilities of one of the top AI startups in addition to enriching 
their drug discovery pipeline."

"We are thrilled to collaborate with Sanofi. Leveraging Sanofi's strong drug 
research and development expertise and Insilico's powerful AI platform, we 
believe we can accelerate novel therapeutics discovery to address diseases with 
unmet medical needs," said Feng Ren, PhD, co-CEO and Chief Scientific Officer 
of Insilico Medicine. "Together we will use cutting-edge AI technologies to 
make significant breakthroughs in drug R&D."

About Insilico Medicine

Insilico Medicine, a clinical stage end-to-end artificial intelligence 
(AI)-driven drug discovery company, is   connecting biology, chemistry, and 
clinical trials analysis using next-generation AI systems. The company has 
developed AI platforms that utilize deep generative models, reinforcement 
learning, transformers, and other modern machine learning techniques to 
discover novel targets and to design novel molecular structures with desired 
properties. Insilico Medicine is delivering breakthrough solutions to discover 
and develop innovative drugs for cancer, fibrosis, immunity, central nervous 
system (CNS) diseases and aging-related diseases.

For more information, visit www.insilico.com  

For business development inquiries, contact bd@insilicomedicine.com

Source: Insilico Medicine